Form 424B5 Avidity Biosciences,
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Total darkness, then sunset as full eclipse wows spectators in Spain
- Burry doubles down on Nebius short after stock surges 34% on earnings
Avidity Biosciences (RNA) PT Raised to $45 at BofA Securities
June 13, 2024 5:17 AM EDTBofA Securities analyst Geoff Meacham raised the price target on Avidity Biosciences (NASDAQ: RNA) to $45.00 (from $40.00) while maintaining a Buy rating.
The analyst comments "This morning, Avidity reported compelling biomarker (>50% reduction in DUX4 related gene panels) and functional strength improvement data in FSHD (a rare muscle disorder) patients treated with... More
